PROTONIX IV Drug Patent Profile

When do Protonix Iv patents expire, and what generic alternatives are available?

Protonix Iv is a drug marketed by Wyeth Pharms and is included in one NDA.

The generic ingredient in PROTONIX IV is pantoprazole sodium. There are forty-eight drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the pantoprazole sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Protonix Iv

A generic version of PROTONIX IV was approved as pantoprazole sodium by APOTEX on January 19^th, 2011.

Summary for PROTONIX IV

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	32
Patent Applications:	5,491
Drug Prices:	Drug price information for PROTONIX IV
DailyMed Link:	PROTONIX IV at DailyMed

See drug prices for PROTONIX IV

Recent Clinical Trials for PROTONIX IV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 2
Mirati Therapeutics Inc.	Phase 1
Assiut University	Phase 2

See all PROTONIX IV clinical trials

Pharmacology for PROTONIX IV

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Proton Pump Inhibitors

Paragraph IV (Patent) Challenges for PROTONIX IV

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROTONIX IV	For Injection	pantoprazole sodium	40 mg/vial	020988	1	2005-04-07

US Patents and Regulatory Information for PROTONIX IV

PROTONIX IV is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	AP	RX	Yes	Yes

Expired US Patents for PROTONIX IV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	4,758,579*PED
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	6,780,881*PED
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	8,754,108*PED
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	7,351,723*PED

International Patents for PROTONIX IV

See the table below for patents covering PROTONIX IV around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2002216042
Hong Kong	86894	Dialkoxyridines, process for their preparation, their application and medicaments containing them
Slovakia	287993
Germany	60132108
Poland	361118
Ukraine	80961	PROCESS FOR OBTAINING OF FREEZE-DRIED PANTOPRAZOLE PREPARATION, LYOPHILIZED PANTOPRAZOLE PREPARATION, INJECTION SOLUTION BASED ON PANTOPRAZOLE AND INJECTION KIT

Supplementary Protection Certificates for PROTONIX IV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0166287	SPC/GB96/056	United Kingdom		PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
0166287	96C0032	Belgium		PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
0166287	96C0033	Belgium		PRODUCT NAME: EPTACOG ALFA (ACTIVATED); REGISTRATION NO/DATE: EU/1/96/006/002 19960223

PROTONIX IV Market Analysis and Financial Projection

Last updated: February 10, 2026

What Is the Market Position of PROTONIX IV?

PROTONIX IV, an intravenous formulation of the proton pump inhibitor pantoprazole, targets hospitals and healthcare facilities for acid-related gastrointestinal conditions. It addresses the needs of patients unable to take oral medication. Its primary competitors include pantoprazole oral formulations and other IV proton pump inhibitors such as esomeprazole and omeprazole.

How Is the Market for IV Proton Pump Inhibitors Evolving?

The global market for intravenous proton pump inhibitors (PPIs) is expanding, driven by increased hospitalization rates and the need for acid suppression in critically ill or post-operative patients. Market size was valued at approximately $780 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.6% through 2030 [1].

Key factors influencing growth include:

• Rising incidence of gastrointestinal bleeding in hospitalized patients.
• Growth in surgical procedures requiring acid suppression.
• Expanding ICU admissions globally.

What Are the Financial Metrics and Sales Trends for PROTONIX IV?

Pfizer's PROTONIX IV accounted for a significant share of the IV PPI segment in the US, generating net sales of approximately $300 million in 2022, representing a year-over-year increase of 4% [2]. The drug benefits from hospital procurement contracts, which stabilize revenue streams but limit rapid growth.

The average purchase price for PROTONIX IV in the US is around $160 per vial, with typical prescriptions involving 1-2 vials per patient. Sales are concentrated in hospital channels, with minimal presence in outpatient or retail pharmacy markets.

What Are the Major Competitive Dynamics?

The competitive landscape includes:

• Oral options like Protonix tablets, which have higher market share in outpatient settings.
• Alternative IV PPIs such as Nexium (esomeprazole), which competes on efficacy and hospital formulary preferences.
• Biosimilar or generic versions that could erode pricing power over time.

Pfizer holds patent protection for PROTONIX IV until 2025 in major markets, though generic versions of pantoprazole are available for oral formulations after 2015, with limited IV equivalents.

What Are the Regulatory and Supply Chain Influences?

PROTONIX IV has FDA approval under New Drug Application (NDA) 022607, with approvals extended to several markets including Europe and Japan. Regulatory approval timelines remain consistent, with lifecycle management strategies focusing on expanding labels and indications.

Supply chain considerations concern manufacturing capacity and raw material costs, notably for the active pharmaceutical ingredient (API). Price pressures on raw materials, especially from suppliers in China and India, influence gross margins.

What Is the Outlook for Growth and Market Share?

Market share for PROTONIX IV in the hospital IV PPI segment hovered around 25% in 2022, with room for growth through:

• Indication expansion, especially in non-ulcer dyspepsia and prophylaxis.
• Market penetration in emerging markets, such as China and India, where hospital infrastructure expands.
• Strategic partnerships with hospital networks and procurement agencies.

However, pricing pressures, the expiration of patent exclusivity in 2025, and generic competition pose risks to sustained revenue growth.

What Are the Key Risks and Opportunities?

Risks include:

• Entry of generics reducing prices.
• Changes in hospital formulary preferences favoring alternative PPIs.
• Regulatory shifts affecting labeling or approval pathways.

Opportunities involve:

• New indications and combination therapy development.
• Digital health integration for targeted delivery.
• Mergers or acquisitions consolidating market share in hospital drug portfolios.

Key Takeaways

• The IV PPI market is growth-oriented but shares strong competitive pressures.
• PROTONIX IV generated approximately $300 million in sales in 2022, with modest growth prospects.
• Market expansion hinges on indication development and geographic penetration.
• Patent expirations and generic entry threaten future pricing and revenue stability.
• Supply chain and raw material costs impact margin sustainability.

FAQs

1. When does Pfizer's patent protection for PROTONIX IV expire?
Patents in major markets, including the US, expire in 2025, enabling generic competition.

2. How does PROTONIX IV compare to oral formulations in the hospital setting?
It addresses specific needs of non-oral patients, with limited crossover into outpatient markets.

3. What are the primary substitutes for IV PPIs?
Oral PPIs, endoscopic therapy, and surgical interventions serve as alternatives depending on clinical indications.

4. Are there recent FDA regulatory updates affecting PROTONIX IV?
No significant recent updates; ongoing lifecycle management strategies focus on expanding labels.

5. How is the global market for IV PPIs expected to evolve?
It is projected to grow at a CAGR of approximately 7.6%, driven by increasing hospitalizations and surgical procedures worldwide.

---

Sources:

[1] MarketsandMarkets. "Proton Pump Inhibitors Market," 2022.
[2] Pfizer Annual Report, 2022.